



**HAL**  
open science

# Chronic liver disease and cirrhosis among patients with hepatitis B virus infection in northern Portugal with reference to the viral genotypes

Ana Mota, Jorge Areias, Margarida Fonseca Cardoso

► **To cite this version:**

Ana Mota, Jorge Areias, Margarida Fonseca Cardoso. Chronic liver disease and cirrhosis among patients with hepatitis B virus infection in northern Portugal with reference to the viral genotypes. *Journal of Medical Virology*, 2010, 83 (1), pp.71. 10.1002/jmv.21939 . hal-00599793

**HAL Id: hal-00599793**

**<https://hal.science/hal-00599793>**

Submitted on 11 Jun 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Chronic liver disease and cirrhosis among patients with hepatitis B virus infection in northern Portugal with reference to the viral genotypes**

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-10-1932.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	28-Jul-2010
Complete List of Authors:	Mota, Ana; ICBAS - Instituto de Ciências Biomédicas Abel Salazar Areias, Jorge; ICBAS - Instituto de Ciências Biomédicas Abel Salazar Cardoso, Margarida; ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto
Keywords:	Hepatitis B, genotypes, liver disease, cirrhosis, Portugal

SCHOLARONE™  
Manuscripts

## 1 TABLES

2 Table 1: Characteristics of patients with and without cirrhosis

	Without cirrhosis		With cirrhosis		P Value
	(n=190)		(n=59)		
	n <sup>a</sup>	(%)	n <sup>a</sup>	(%)	
<b>Female</b>					
Genotype					0.554 <sup>c</sup>
A	20/83	(24.1)	7/19	(36.8)	
C	0/83	(0.0)	0/19	(0.0)	
D	55/83	(66.3)	12/19	(63.2)	
E	4/83	(4.8)	0/19	(0.0)	
F	4/83	(4.8)	0/19	(0.0)	
D and F	0/83	(0.0)	0/19	(0.0)	
Presumed source of					d
<b>HBV infection</b>					
Perinatal	20/83	(24.1)	4/19	(21.1)	
Sexual	13/83	(15.7)	2/19	(10.5)	
Intrafamilial	29/83	(34.9)	6/19	(31.6)	
Others <sup>b</sup>	21/83	(25.3)	7/19	(36.8)	
Alcohol intake > 20g/day	25/70	(35.7)	6/18	(33.3)	0.850
Mean Age (± SD)	44.1	(±12.9)	48.5	(± 19.1)	0.354
<b>Male</b>					
Genotype					0.742 <sup>c</sup>

A	37/107	(34.6)	13/40	(32.5)	
C	0/107	(0.0)	0/40	(0.0)	
D	60/107	(56.1)	26/40	(65.0)	
E	6/107	(2.8)	0/40	(0.0)	
F	3/107	(2.8)	1/40	(2.5)	
D and F	1/107	(0.9)	0/0	(0.0)	
Presumed source of HBV infection					0.013
Perinatal	29/107	(27.1)	3/40	(7.5)	
Sexual	13/107	(12.1)	12/40	(30.0)	
Intrafamilial	23/107	(21.5)	10/40	(25.0)	
Others <sup>b</sup>	42/107	(39.3)	15/40	(37.5)	
Alcohol intake > 20g/day	53/96	(55.2)	21/37	(61.8)	0.872
Mean Age ( $\pm$ SD) <sup>c</sup>	41.5	( $\pm$ 13.9)	50.8	( $\pm$ 15.9)	0.001

<sup>a</sup>Total for each variable may not sum to the sample size due to missing data.

<sup>b</sup>Other sources, including at least one incidence of intravenous drug use, blood transfusion, occupational exposure, iatrogenic exposure (for example, endoscopy or colonoscopy, history of surgery, acupuncture or haemodialysis), or unknown.

<sup>c</sup>Evaluated only for genotypes A and D.

<sup>d</sup>The necessary statistical assumptions were not met.

9 Table 2 - Patients with cirrhosis (n=59) classified by Child's grade

	<b>n</b>	<b>(%)</b>
<b>Female</b>		
Child's grade A	15/19	(78.9)
Child's grade B	3/19	(15.8)
Child's grade C	1/19	(5.3)
<b>Male</b>		
Child's grade A	24/40	(60.0)
Child's grade B	14/40	(35.0)
Child's grade C	2/40	(5.0)

10

11 Table 3: Comparison of the characteristics of patients with cirrhosis classified as Child's  
 12 grade A and Child's grade B (n= 56)

Characteristics	Child-Pugh A (n=39)		Child-Pugh B (n=17)		P Value
	n <sup>a</sup>	(%)	n <sup>a</sup>	(%)	
Gender					0.222
Female	15/39	(38.5)	3/17	(17.6)	
Male	24/39	(61.5)	14/17	(82.4)	
Genotypes					0.844 <sup>c</sup>
A	15/39	(38.5)	5/17	(29.4)	
C	0/39	(0.0)	0	(0.0)	
D	24/39	(61.5)	11/17	(64.7)	
E	0	(0.0)	0	(0.0)	
F	0	(0.0)	1/17	(5.9)	
D and F	0	(0.0)	0	(0.0)	
Presumed source of HBV infection					
Perinatal	7/39	(17.9)	0	(0.0)	<sup>c</sup>
Sexual	10/39	(25.6)	4/17	(23.5)	
Intrafamilial	10/39	(25.6)	5/17	(29.4)	
Others <sup>b</sup>	12/39	(30.8)	8/17	(47.1)	
Alcohol intake > 20g/day	12/36	(33.3)	13/16	(81.2)	0.004
Mean age (± SD)	44.5	(±16.6)	59.9	(±11.4)	0.001
Viral markers					
Anti-HBc positive	39/39	(100.0)	17/17	(100.0)	<sup>d</sup>
HBeAg negative	24/39	(61.5)	14/17	(82.4)	0.222
Anti-HBe positive	22/39	(56.4)	14/17	(82.4)	0.119
Viral load Geom. Mean	1,400,024.1	(450,584.1;	384,269.7	(60,657.6;2,434,373.5)	0.212

(CI95%) 4,350,059.2)

Biochemistry parameters

greater than reference values

ALT	27/39	(69.2)	10/17	(58.8)	0.653
AST	23/39	(59.0)	15/17	(88.2)	0.065
AP	3/37	(8.1)	6/17	(35.3)	0.021
GGT	11/37	(29.7)	9/17	(52.9)	0.181
AFP	2/32	(6.2)	3/16	(18.8)	0.316

Haematological parameters

Mean ( $\pm$  SD)

Platelet $\times 10^9/L$	163.3	( $\pm 57.8$ )	100.1	( $\pm 48.2$ )	<0.001
MCV	90.5	( $\pm 8.8$ )	94.0	( $\pm 6.5$ )	0.164
PT	13.2	( $\pm 3.0$ )	16.1	( $\pm 5.5$ )	0.013

<sup>a</sup>Total for each variable may not sum to the sample size due to missing data.

<sup>b</sup>Other sources, including at least one incidence of intravenous drug use, blood transfusion, occupational exposure, iatrogenic exposure (for example, endoscopy or colonoscopy, history of surgery, acupuncture or haemodialysis), or unknown.

<sup>c</sup>Evaluated only with genotypes A and D.

<sup>d</sup>The necessary statistical assumptions were not met.

1  
2  
3 **Chronic liver disease and cirrhosis among patients with hepatitis B virus infection in**  
4 **northern Portugal with reference to the viral genotypes**  
5  
6

7  
8 **RUNNING TITLE: Liver disease and cirrhosis among patients with HBV in Portugal**  
9

10 Ana Mota,<sup>1,2</sup>Jorge Areias,<sup>1,3</sup> Margarida Fonseca Cardoso<sup>1,4,5\*</sup>  
11  
12

13  
14  
15 <sup>1</sup>ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.  
16

17 <sup>2</sup>Serviço de Hematologia Clínica, Hospital de Santo António (HSA), Centro Hospitalar do Porto  
18 (CHP), Porto, Portugal. Largo Professor Abel Salazar, 4099-001 Porto.  
19

20 <sup>3</sup>Serviço de Gastrenterologia, Hospital de Santo António (HSA), Centro Hospitalar do Porto (CHP),  
21 Porto, Portugal. Largo Professor Abel Salazar, 4099-001 Porto  
22  
23

24 <sup>4</sup>CIIMAR - Centro Interdisciplinar de Investigação Marinha e Ambiental, Porto, Rua dos  
25 Bragas, 289, 4050-123 Porto, Portugal.  
26  
27

28 <sup>5</sup>ISPUP - Instituto de Saúde Pública da Universidade do Porto, Rua das Taipas, 135-139,  
29 4050-600 Porto, Portugal.  
30  
31

32  
33  
34  
35  
36  
37 \*Correspondence to:

38 Margarida Fonseca Cardoso  
39

40 Instituto de Ciências Biomédicas de Abel Salazar  
41

42 Universidade do Porto,  
43

44 Largo Prof. Abel Salazar, 2  
45

46 4099-003 Porto  
47

48 PORTUGAL  
49

50 Phone: + 351 22 206 22 79  
51

52 Fax: + 351 22 206 22 32  
53

54 E-mail: mcard@icbas.up.pt  
55  
56  
57  
58  
59  
60



**ABSTRACT**

The prevalence of infection with hepatitis B virus in Portugal is around 1% of the population; 20-30% of those infected typically develop cirrhosis. The study focuses on the epidemiological profile of patients with hepatitis B infection and liver damage, in particular, cirrhosis. Of the 358 individuals that comprised the study, a liver biopsy was performed in 249 to identify the presence of cirrhosis. Cirrhosis was observed in 59 patients (23.7%) The Child-Pugh classification was used to assess the prognosis of cirrhosis: 3 out of the 59 patients were classified as Child-Pugh grade C, the most severe, 17 (28.8%) as grade B and 39 (66.2%) as grade A. Patients classified as grade B were older, drank more and showed higher levels of AST and alkaline phosphatase when compared with individuals classified as grade A. Genotypes A and D were predominant, and no significant differences with respect to genotype distribution were observed. Analysis of the haematological parameters showed that patients classified as Child's grade B had lower levels of Platelets and higher levels of prothrombin time than those classified as Child's grade A. The profile of the patients with cirrhosis, including an extended number of individual characteristics, provides useful information, however, only a prospective study could evaluate definitively if liver disease is influenced by these factors. Future studies would benefit from the analysis of the impact of genotypes on liver disease, particularly genotypes A and D, the most predominant genotypes in northern Portugal.

**KEY WORDS:** Hepatitis B, genotypes, liver disease, cirrhosis, Portugal.

## INTRODUCTION

Cirrhosis occurs in 20-30% of those patients who are infected chronically with the hepatitis B virus (HBV). About 25% of these may develop hepatocellular carcinoma (HCC). In patients with chronic HBV and HCC, the genetic material of HBV is frequently found to be part of the genetic material of the cancer cells. The HBV genetic material enters the normal liver cells and disrupts their function, and may lead to transformation into cancerous cells. Because of the genetic mutation caused by HBV, a patient with HBV infection may develop HCC with or without cirrhosis.

Persistent hepatitis B infection affects 350–400 million people worldwide (Lee 1997; Yuen et al. 2009). These patients are at least 100 times more likely to develop hepatocellular carcinoma (HCC) compared with uninfected individuals (Beasley et al. 1981). HCC is the leading cause of death in patients with cirrhosis (Varela et al. 2009). Several potential factors have been linked with a higher risk of developing HCC, including male gender, advanced age, virological factors such as hepatitis B *e* antigen positivity and high serum HBV DNA levels (Sherman 2005).

The association between HBV genotypes and severity of liver disease remains debatable, although one study has found more fibrosis in patients with genotype A than with genotype D (Halfon et al. 2006).

Portugal is populated by approximately 10 million inhabitants, with an immigrant community of around 4%. Immigrants are concentrated in the south with an epicentre in Lisbon while the north of the country has relatively fewer immigrants (MAI 2008). At present, there is no information on the prevalence of HBV infection in Portugal. According to the most representative research in this field, patients chronically infected with HBV comprise approximately 0.36 to 1% of the Portuguese population (Lecour et al. 1984; Santos et al. 2000; Ministério da Saúde 2004).

1  
2  
3 The results of the study are part of a project in progress at a Portuguese university to  
4 characterize the epidemiological profile of the hepatitis B virus in northern Portugal (Mota et  
5 al. 2009; Mota et al. 2010). This study, within the ambit of a larger project, focuses on the  
6 epidemiological profile of liver damage, particularly cirrhosis, in patients infected chronically  
7 with hepatitis B virus.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

## MATERIALS AND METHODS

### Study design

Data were obtained as part of an epidemiological study of the hepatitis B virus in northern Portugal (Mota et al. 2009). From a group of 358 individuals with chronic hepatitis B virus infection, serum samples were tested for HBsAg, antibodies to HBsAg (anti-HBs), antibodies to the HBV core antigen (anti-HBc), HBeAg, and antibodies to HBeAg (anti-HBe). HBV genotypes were determined along with other biochemical and haematological parameters. The present study includes the 249 patients who underwent histological evaluation.

### Patients

Patients with hepatitis B infection were identified by the presence of HBsAg in their serum for at least 6 months. The majority of patients from the north of Portugal, are treated in three hospitals in the city of Oporto: Hospital de Santo António, Hospital Joaquim Urbano and Hospital de São João. The patients in this study were examined in 2008 and 2009 in the Hospital de Santo António and Hospital Joaquim Urbano. The study was approved by the Health Ethics Committee of Hospital de Santo António, and written consent was obtained from all participants.

### Clinical findings

Information related to the demographics, clinical, histological and medical history of the patients was retrieved from medical files.

### Biochemical tests of liver function and other blood parameters

The blood tests considered when assessing liver function included: alanine aminotransferase (ALT) (reference values 10 to 36 U/L at 37°C) and aspartate aminotransferase (AST) (reference values 10 to 30 U/L at 37°C), which are contained within liver cells, gamma-

1  
2  
3 glutamyltranspeptidase (GGT) (reference values 10 to 66 U/L at 37°C), alkaline phosphatase  
4  
5 (AP) (reference values 45 to 122 U/L at 37°C), and alpha-fetoprotein (AFP) (reference values  
6  
7 less than 10.9 ng/ml). Haematological parameters like mean corpuscular volume (MCV), and  
8  
9 platelets were also evaluated using an Advia 120 System (Bayer, New York, USA).  
10  
11 Prothrombin time (PT) measurement was performed using an ACL TOP system  
12  
13 (Instrumentation Laboratory Company, Lexington, USA).  
14  
15  
16  
17

### 18 **Detection of virological markers in serum**

19  
20  
21 HBsAg, anti-HBs and anti-HBc, HBeAg, and anti-HBe antibodies were evaluated using a  
22  
23 Vitros ECI assays (Ortho-Clinical Diagnostics, Amersham, Buckinghamshire, UK).  
24  
25  
26

### 27 **HBV DNA quantitation**

28  
29  
30 HBV DNA levels were determined using the Versant<sup>®</sup>HBV DNA 3.0 assay (bDNA) (Bayer,  
31  
32 New York, USA). The assay quantitation range is 357-17,900,000 HBV DNA IU/ml.  
33  
34  
35

### 36 **HBV Genotyping**

37  
38  
39 HBV genotypes were identified by the Trugene<sup>®</sup> HBV genotyping kit in conjunction with the  
40  
41 Open Gene<sup>®</sup> DNA Sequencing System (Bayer, New York, USA).  
42  
43  
44

### 45 **Cirrhosis**

46  
47  
48 Cirrhosis was evaluated by liver biopsy.  
49  
50

### 51 **Child-Pugh classification**

52  
53 This classification was used to assess the prognosis of cirrhosis. Child's grading of severity in  
54  
55 chronic liver disease was classified along with Pugh's 1973 modifications (Pugh et al. 1973)  
56  
57 and based upon information recorded from medical files. The classification has three grades,  
58  
59  
60

1  
2  
3 from A to C with grade C being the severest. The respective overall 5-year mortality rates for  
4  
5 grades C to A are 88%, 38%, and 29%.  
6  
7

### 8 **Statistical analysis**

9

10  
11 Statistical analysis was performed with SPSS (version 16.0) and two-sided significance tests  
12  
13 at the 5% level were used throughout.  
14

15  
16 Qualitative variables were described as percentages and quantitative variables as means, or  
17  
18 geometric means where necessary. The distribution of viral load was logarithmically  
19  
20 transformed and the results are given as geometric means with 95% confidence intervals. For  
21  
22 the other quantitative variables, results were given as arithmetic means ( $\pm$ standard deviation).  
23

24  
25 Proportions were compared using the Pearson chi-square test (with continuity correction) as  
26  
27 appropriate, or by Fisher's exact test. Continuous variables were compared using the *t*-test,  
28  
29 after log transformation so that assumptions were met, if necessary. Multivariable analysis  
30  
31 was not considered due to the reduced number of individuals when subdivided by cirrhosis,  
32  
33 gender and the Child's grading of disease severity for chronic liver disease.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

Liver biopsy was performed on 249 patients for histological assessment. Cirrhosis was found in 59 patients (23.7%).

Genders were analyzed separately, and patients with and without cirrhosis were compared. Genotypes A and D were predominant, and no significant differences between the study groups were observed with respect to genotype distribution, in both genders (Table 1). The distribution of the presumed sources of transmission of viral infection was similar among female patients, while sexual transmission was an increased factor in male patients with cirrhosis ( $p=0.013$ ). Alcohol intake levels (less or more than 20g/day) were similar between the two groups with or without cirrhosis. On average, male patients with cirrhosis were older than patients without cirrhosis ( $p=0.001$ ), while the same was true with female patients the relationship was not significant.

(Table 1)

In patients with cirrhosis, liver disease severity was evaluated using Child's grading of disease severity with Pugh's modifications (Table 2).

(Table 2)

Evaluation of the 59 patients, 32.2% female, was carried out according to the Child-Pugh classification. In the female group, Child's grade A classification was the most frequent (78.9%) and only one woman was classified as Child's grade C. On the other hand, an increased proportion of Child's grade B classification was observed in men (35% versus 15.8% in women) while two were classified as Child's grade C.

### Child's grade equivalent C

Only three patients scored sufficiently to receive a Child-Pugh classification level C, two of them being male. All patients were genotype D, and aged between 66 and 80 years old. The

1  
2  
3 presumed source of infection is unknown in two patients while the third patient had a reported  
4  
5  
6 intrafamilial transmission of HBV infection. All patients (n=3) were HBeAg negative, and all  
7  
8 of them also presented viral load of HBV greater than 357-HBV DNA IU/ml.  
9

10  
11 Biochemical tests revealed ALT was elevated in two individuals, AST in all three, while only  
12  
13 one occurrence of elevated alkaline phosphatase, GGT and alpha-fetoprotein was found.  
14

### 15 16 17 **Child's grade equivalent A and B**

18  
19  
20 Individuals classified as Child's grade A (n=39) and B (n=17) were compared by gender,  
21  
22 genotype, the presumed source of infection, alcohol intake, place of birth, median age, viral  
23  
24 markers, viral load and biochemistry parameters (Table 3).  
25

26  
27  
28 (Table 3)  
29

30  
31 When patients with cirrhosis, were compared by gender, genotype and the presumed source of  
32  
33 infection, no significant differences between Child's grade A and B were found. Individuals  
34  
35 classified as Child's grade B were older and had a significantly higher proportion of patients  
36  
37 with alcohol intake above 20g/day ( $p \leq 0.004$ ). Patients classified as Child's grade B showed a  
38  
39 tendency to have higher proportions of elevated biochemistry parameters like AST, alkaline  
40  
41 phosphatase, GGT and alpha-fetoprotein when compared with individuals classified as grade  
42  
43  
44  
45 A.  
46

47  
48 Haematological parameters were also compared (Table 3). Patients classified as Child's grade  
49  
50 B had significantly lower levels of platelets ( $p < 0.001$ ) and significant higher levels of  
51  
52 prothrombin time ( $p = 0.013$ ) than patients classified as Child's grade equivalent A.  
53  
54  
55  
56  
57  
58  
59  
60



## DISCUSSION

This study is one of the first attempts to describe the epidemiological profile of liver damage, particularly cirrhosis, in patients infected chronically with hepatitis B virus in Portugal. Both patients with and without cirrhosis formed part of the study.

All patients in the study were from the north of Portugal. In the sample of patients infected with HBV who underwent histological evaluation (n=249) the results showed that there was a considerable proportion with an increased incidence of liver damage, while 23.7% of the patients had cirrhosis. Genotypes A and D were predominant in patients with or without cirrhosis. A previous study in the north of Portugal (Mota et al. 2009) found genotypes A and D to be predominant, with genotype D accounting for 60.1% and genotype A accounting for 30.1% of the patients evaluated. In Spain, the only country that borders Portugal, genotypes A and D have been also found to be prevalent (Echevarria and Leon 2004; Basaras et al. 2007), although the relationship with the stage of cirrhosis is undocumented. A study in India found that genotype D was associated with more severe liver diseases when compared with genotype A. Genotype D was more prevalent in HCC patients less than 40 years of age, when compared with asymptomatic carriers (Thakur et al. 2002). Similar results are likely to be found in the north of Portugal, given a suitably large sample size.

In this study a statistical association was not found between cirrhosis and genotypes of HBV ( $p \leq 0.554$ ), or alcohol consumption level ( $p \leq 0.850$ ), for both male and female patients. Comparison between patients without and with cirrhosis showed a tendency for patients with cirrhosis to be older. Recent studies have shown that, older age, male gender and cirrhosis were the major risk factors associated with the development of HCC (Lok 2009).

In this study a classification system developed to assess the severity of liver cirrhosis, the Child-Pugh grade, was chosen to evaluate patients. In the study sample, 3 out of the 59

1  
2  
3 patients were classified as Child-Pugh grade C, the most severe, 17 (28.8%) as grade B and  
4  
5 39 (66.2%) as grade A.  
6  
7

8  
9 To understand better what factors are associated with the severity of liver disease those  
10 patients with cirrhosis classified as Child-Pugh grade B were compared with the group  
11 classified with the less severe grade, A, in terms of HBV genotypes, patient demographics  
12 and alcohol intake, transmission routes, virological markers for HBV, viral load, liver  
13 enzymes, and hematological parameters. In this study a statistical association was not found  
14 between severity of liver disease and gender ( $p=0.222$ ), genotypes, ( $p=0.844$ ), eventual  
15 transmission routes of infection, HBeAg negativity ( $p=0.222$ ), anti-HBe positive ( $p=0.119$ )  
16 and viral load ( $p=0.212$ ). All patients were anti-HBc positive. The analysis showed that  
17 patients classified as Child-Pugh grade B were older ( $p=0.001$ ) and had a significantly higher  
18 percentage of alcohol intake above 20g/day ( $p=0.004$ ) when compared to individuals  
19 classified as Child-Pugh grade A. The same trend has been observed previously when  
20 studying the relationship between the severity of liver disease and age and alcohol  
21 consumption (Mota et al. 2010). While this previous study reported a relationship between  
22 alcohol consumption and liver disease severity, a relaxed definition of liver disease was used,  
23 including patients with and without histological evaluation, and patients without disease  
24 reports. The present study, restricted only to patients with cirrhosis, achieved the same  
25 positive association between age, alcohol intake and severity of liver disease. Age and alcohol  
26 consumption were also reported as risk factors associated with HCC in many studies from  
27 different countries, including Portugal (Pereira et al. 1994; Oliveira 2001; Wang et al. 2003;  
28 Chung et al. 2007).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55  
56 Hepatitis B infection may influence the development of liver disease in heavy alcohol  
57 drinkers in several ways. Firstly, persistent infection with HBV might encourage alcohol  
58 induced liver damage, and evidence exists that this may occur at fairly low levels of alcohol  
59  
60

1  
2  
3 intake (Villa et al. 1982). On the other hand, chronic active hepatitis associated with HBsAg  
4  
5 may coexist with alcoholic liver disease, and the two disease processes would probably result  
6  
7 in more rapid progression to cirrhosis. For this reason a vaccination program would be of  
8  
9 great benefit to excessive drinkers, as infection with HBV and Hepatitis C virus (HCV) are  
10  
11 major contributing factors towards the development of HCC (Nalpas et al. 1998). Alcohol  
12  
13 dependent patients under treatment or attended to by emergency hospital services, are  
14  
15 opportunities for preventive intervention. Such patients should be checked for viral diseases  
16  
17 like hepatitis C, human immunodeficiency virus (HIV) and HBV infection. In all individuals  
18  
19 without evidence of infection with HBV, a vaccination should be implemented.  
20  
21  
22  
23  
24

25 The pattern observed for patients without hepatitis B *e* antigen and viral load, in patients with  
26  
27 chronic hepatitis B, seems to be predominant in Mediterranean countries. Additionally some  
28  
29 investigators have found that HBV infection remained active after seroconversion to anti-HBe  
30  
31 in nearly 40% of patients (Rodriguez-Frias et al. 1995; Grandjacques et al. 2000). In France,  
32  
33 an increasing prevalence of HBeAg negative was observed (Zarski et al. 2006), in accordance  
34  
35 with this study of Portugal, with probable basal promoter core or a precore region mutations  
36  
37 (two individuals presented anti-HBc negative). The knowledge of this characteristic is very  
38  
39 important for optimizing clinical management and future therapeutic trials for chronic  
40  
41 hepatitis B. Particularly, with respect to HBV replication status, HBV genotype and mutations  
42  
43 in the basal core promoter region play an important role in the HCC development (Lok 2009).  
44  
45 Many factors seem to contribute to the development of HCC: host and viral risk factors  
46  
47 associated with increased risk of cirrhosis or HCC include older age (longer duration of  
48  
49 infection), alcohol consumption, smoking, HBV genotype C, high levels of HBV DNA and  
50  
51 concurrent infection with hepatitis like HCV, hepatitis D virus (HDV) or HIV (Fattovich et al.  
52  
53 1995; McMahon et al. 2001; Fattovich 2003; Yim and Lok 2006).  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This Portuguese study showed that ALT levels in patients with Child's grade A and B had  
4 similar values. On the other hand, Child's grade B patients, showed a higher proportion with  
5 elevated levels of AST and alkaline phosphatase, when compared with individuals classified  
6 as grade A. Even in this Portuguese study, patients classified as Child's grade equivalent B  
7 had significantly lower levels of platelets ( $p<0.001$ ) and significant higher levels of PT  
8 ( $p=0.013$ ) compared to the Child's grade equivalent A. Thrombocytopenia is considered as a  
9 valid surrogate of cirrhosis and a valid marker for the identification of individuals at high-risk  
10 for HCC (Lu et al. 2006). Although not significant, Child's grade B individuals presented  
11 elevated values for GGT and AFP.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 In conclusion, the present study examined the associations between cirrhosis, and an extended  
26 number of patient's characteristics, providing useful information on the profile of patients  
27 infected with hepatitis B virus in northern Portugal. The group of patients with cirrhosis,  
28 classified as Child-Pugh grade B, was older and showed elevated levels of alcohol intake.  
29 Comparison of patients classified as Child-Pugh grade B with individuals classified as Child-  
30 Pugh grade A, showed a higher proportion of biochemical parameters particularly, AST, AP,  
31 GGT and elevated AFP, with hematological parameters showing lower platelet levels and  
32 higher PT values.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 In the evaluation of cirrhosis, liver biopsy continues to be the preferred diagnostic method,  
46 but the appearance of 'stiffness' measurement techniques will probably be the eventual future  
47 diagnosis of cirrhosis. However, additional studies are needed for the evaluation of liver  
48 fibrosis possibly based on liver 'stiffness' measurements, and cutoff values must be defined  
49 for categorizing the different stages of cirrhosis.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Although no association between HBV genotypes and severity of liver disease was observed  
4  
5 with the sample evaluated, it would be important in future investigations to determine the  
6  
7 impact of genotypes on liver disease, particularly cirrhosis.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

1  
2  
3  
4  
5  
6 **Conflict of interest**  
7

8  
9 The authors disclose that there are no financial or personal relationships with other people or  
10 organizations that could inappropriately influence their work during the submission process.  
11  
12

13  
14 **Acknowledgments:**  
15

16  
17 This study was supported by a grant from Forum Hematológico do Norte, Porto, Portugal.  
18

19  
20 The authors would like to thank J.H. Tice for scientific English editing.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**BIBLIOGRAPHY**

- 1  
2  
3  
4  
5  
6  
7 Basaras M, Arrese E, Blanco S, Sota M, de las Heras B, Cisterna R. 2007. Characterization of  
8  
9 hepatitis B virus genotypes in chronically infected patients. *Rev Esp Quimioter* 20(4):  
10  
11 442-445.  
12  
13  
14 Beasley RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellular Carcinoma and Hepatitis B  
15  
16 Virus: A Prospective Study of 22 707 Men in Taiwan. *Lancet* 318(8256): 1129-1133.  
17  
18  
19 Chung NS, Kwon OS, Park CH, Kim YN, Cho GH, Lee JJ, Kim GH, Kim HO, Ko KI, Yu  
20  
21 SK, Kwon KA, Kim YS, Choi DJ, Kim JH. 2007. [A comparative cross-sectional  
22  
23 study of the development of hepatocellular carcinoma in patients with liver cirrhosis  
24  
25 caused by hepatitis B virus, alcohol, or combination of hepatitis b virus and alcohol].  
26  
27 *Korean J Gastroenterol* 49(6): 369-375.  
28  
29  
30 Echevarria JM, Leon P. 2004. Hepatitis B virus genotypes identified by a Line Probe Assay  
31  
32 (LiPA) among chronic carriers from Spain. *Enferm Infecc Microbiol Clin* 22(8): 452-  
33  
34 454.  
35  
36  
37 Fattovich G. 2003. Natural history and prognosis of hepatitis B. *Semin Liver Dis* 23(1): 47-  
38  
39 58.  
40  
41  
42 Fattovich G, Giustina S, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P,  
43  
44 Christensen E, Krogsgaard K, Degos F, Carneiro de Moura M. 1995. Occurrence of  
45  
46 hepatocellular carcinoma and decompensation in western European patients with  
47  
48 cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis.  
49  
50 *Hepatology* 21(1): 77-82.  
51  
52  
53  
54 Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M,  
55  
56 Trépo C, Zoulim F. 2000. Rapid detection of genotypes and mutations in the pre-core  
57  
58 promoter and the pre-core region of hepatitis B virus genome: correlation with viral  
59  
60 persistence and disease severity. *J Hepatol* 33(3): 430-439.

- 1  
2  
3 Halfon P, Bourliere M, Pol S, Benhamou Y, Ouzan D, Rotily M, Khiri H, Renou C,  
4  
5 Pénaranda G, Saadoun D, Thibault V, Serpaggi J, Varastet M, Tainturier MH, Poynard  
6  
7 T, Cacoub P. 2006. Multicentre study of hepatitis B virus genotypes in France:  
8  
9 correlation with liver fibrosis and hepatitis B e antigen status. *J Viral Hepat* 13(5):  
10  
11 329-335.  
12  
13  
14  
15 Lecour H, Ribeiro AT, Amaral I, Rodrigues MA. 1984. Prevalence of viral hepatitis markers  
16  
17 in the population of Portugal. *Bull World Health Organ* 62: 743-747.  
18  
19  
20 Lee WM. 1997. Hepatitis B virus infection. *N Engl J Med* 337(24): 1733-1745.  
21  
22  
23 Lok AS. 2009. Hepatitis B: liver fibrosis and hepatocellular carcinoma. *Gastroenterol Clin*  
24  
25 *Biol* 33(10-11): 911-915.  
26  
27  
28 Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Huang WS, Lee CM, Chen CC, Changchien  
29  
30 CS. 2006. Thrombocytopenia as a surrogate for cirrhosis and a marker for the  
31  
32 identification of patients at high-risk for hepatocellular carcinoma. *Cancer* 107(9):  
33  
34 2212-2222.  
35  
36  
37 MAI. 2008. Foreign Population in Portugal (2007). Ministry of Internal Affairs (MAI).  
38  
39  
40 McMahon BJ, Holck P, Bulkow L, Snowball M. 2001. Serologic and clinical outcomes of  
41  
42 1536 Alaska Natives chronically infected with hepatitis B virus. *Ann Intern Med*  
43  
44 135(9): 759-768.  
45  
46  
47 Ministério da Saúde DGS. 2004. Avaliação do programa nacional de vacinação e melhoria do  
48  
49 seu custo-efectividade: 2º inquérito serológico nacional: Portugal Continental 2001-  
50  
51 2002.  
52  
53  
54 Mota A, Guedes F, Areias J, Pinho L, Cardoso MF. 2009. Epidemiological Study of  
55  
56 Genotypes of Hepatitis B virus in Northern Portugal. *Journal of Med Virol* 81: 1170-  
57  
58 1176.  
59  
60



- 1  
2  
3 Mota A, Guedes F, Areias J, Pinho L, Cardoso MF. 2010. Alcohol consumption among  
4 patients with hepatitis B infection in northern Portugal considering gender and  
5 hepatitis B virus genotype differences. *Alcohol* 44: 149-156.  
6  
7  
8  
9  
10 Nalpas B, Pol S, Thépot V, Zylberberg H, Berthelot P, Bréchet C. 1998. ESBRA 1997 Award  
11 lecture: relationship between excessive alcohol drinking and viral infections. *Alcohol*  
12 33(3): 202-206.  
13  
14  
15  
16  
17 Oliveira J, Ferreira P, Sá A. 2001. Carcinoma hepatocelular: Casuística do Serviço de  
18 Medicina III dos Hospitais da Universidade de Coimbra. *Rev Gastroenterol Cir* 18(95):  
19 112-121.  
20  
21  
22  
23  
24 Pereira FE, Goncalves CS, Gonçalves MP. 1994. The effect of ethanol intake on the  
25 development of hepatocellular carcinoma in HBsAg carriers. *Arq Gastroenterol* 31(2):  
26 42-46.  
27  
28  
29  
30  
31 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. 1973. Transection of the  
32 oesophagus for bleeding oesophageal varices. *Br J Surg* 60(8): 646-649.  
33  
34  
35  
36 Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R, Guardia J. 1995.  
37 Hepatitis B virus infection: precore mutants and its relation to viral genotypes and  
38 core mutations. *Hepatology* 22(6): 1641-1647.  
39  
40  
41  
42  
43 Santos A, Carvalho A, Tomaz J, Rodrigues V, Coxinho L, Bento D, Sa R, Porto A. 2000.  
44 Prevalence of markers of hepatitis B infection in the adult population of the district of  
45 Coimbra. *Acta Med Port* 13(4): 167-171.  
46  
47  
48  
49  
50 Sherman M. 2005. Hepatocellular Carcinoma: Epidemiology, Risk Factors, and Screening.  
51 *Semin Liver Dis* 25(02): 143-154.  
52  
53  
54  
55 Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. 2002. Profile, spectrum and  
56 significance of HBV genotypes in chronic liver disease patients in the Indian  
57 subcontinent. *J Gastroenterol Hepatol* 17(2): 165-170.  
58  
59  
60

- 1  
2  
3 Varela M, Reig M, Mata ML, Matilla A, Bustamante J, Pascual S, Turnes J, Aracil C, Val  
4  
5 AD, Pascasio JM, Rodriguez M, Bruix J. 2010. [Treatment approach of hepatocellular  
6  
7 carcinoma in Spain. Analysis of 705 patients from 62 centers.]. *Med Clin (Barc)*  
8  
9 134(13):569-576.  
10  
11
- 12 Villa E, Rubbiani L, Barchi T, Ferretti I, Grisendi A, De Palma M, Bellentani S, Manenti F.  
13  
14 1982. Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced  
15  
16 hepatic damage. *Lancet* 2(8310): 1243-1244.  
17  
18
- 19 Wang LY, You SL, Lu SN, Ho HC, Wu MH, Sun CA, Yang HI, Chien-Jen C. 2003. Risk of  
20  
21 hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and  
22  
23 cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-  
24  
25 seronegative male residents in Taiwan. *Cancer Causes Control* 14(3): 241-250.  
26  
27
- 28 Yim HJ and Lok AS. 2006. Natural history of chronic hepatitis B virus infection: what we  
29  
30 knew in 1981 and what we know in 2005. *Hepatology* 43(2 Suppl 1): S173-81.  
31  
32
- 33 Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, A. Chan O, Wong BC,  
34  
35 Mizokami M, Lai CL. 2009. Independent risk factors and predictive score for the  
36  
37 development of hepatocellular carcinoma in chronic hepatitis B. *Journal of*  
38  
39 *Hepatology* 50(1): 80-88.  
40  
41
- 42 Zarski JP, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne-Carrie N, Barange K, Canva V,  
43  
44 Doffoel M, Calles P. 2006. Characteristics of patients with chronic hepatitis B in  
45  
46 France: predominant frequency of HBe antigen negative cases. *J Hepatol* 45(3): 355-  
47  
48 360.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60